pharma · Breast Cancer · Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease
Pierre Fabre Medicament
PIERRE FABRE MEDICAMENT is a pharma organization headquartered in LAVAUR, FR. Primary therapeutic focus areas include Breast Cancer, Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease, X-linked hyp
LAVAUR, FR HQ
176 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- LAVAUR, FR
- Employees
- 176
- Programs
- 8
- Drugs
- 13
- Patents
- 0
ER004
Phase 2 · small molecule · X-linked hypohidrotic ectodermal dysplasia (XLHED)
ER004 for X-linked hypohidrotic ectodermal dysplasia (XLHED) is a Phase 2 program (small_molecule) at Pierre Fabre Medicament with 1 ClinicalTrials.gov record(s).
Internal code EDELIFE
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pierre Fabre Medicament
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- X-linked hypohidrotic ectodermal dysplasia (XLHED)
- Status
- active
- Trials
- 1